Aastrom Biosciences Announces First Patients Treated In IxCELL-DCM Clinical Study Of Ixmyelocel-T

ANN ARBOR, Mich., April 19, 2013 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded multicellular therapies for the treatment of severe, chronic cardiovascular diseases, today announced that the first patients were treated in the ixCELL-DCM Phase 2b clinical trial. This study is evaluating the safety and efficacy of ixmyelocel-T compared to placebo in patients with advanced heart failure due to ischemic dilated cardiomyopathy (ischemic DCM). Aastrom has received U.S. orphan drug designation for the use of ixmyelocel-T in patients with DCM.  

"There is an unmet need for additional treatment options for DCM as this condition significantly reduces quality of life and places patients at high risk of multiple hospitalizations and increased mortality. The survival rate for DCM drops to just 30% after five years. Ixmyelocel-T has been shown to promote tissue repair in the heart, which can potentially improve outcomes for the hundreds of thousands of people who suffer from advanced heart failure," said Dr. Safwan Kassas, interventional cardiologist, director of the stem cell and regenerative medicine program at the Michigan CardioVascular Institute/Covenant Medical Center and principal investigator in the ixCELL-DCM trial. 

The ixCELL-DCM trial is a randomized, double-blind, placebo-controlled phase 2b study with a planned enrollment of 108 patients at approximately 30 sites in the U.S. In the study, ixmyelocel-T will be administered via catheter-based injections to patients with advanced heart failure due to ischemic DCM.  The primary endpoint of the trial will be the average number of events per patient, which include all-cause mortality, all-cause hospitalizations or unplanned hospital visits to treat worsening heart failure over 12 months.

"We are very enthusiastic about evaluating the therapeutic potential of ixmyelocel-T to treat patients with DCM, and grateful to our study coordinators and investigators for their progress in moving this important clinical program forward," said Nick Colangelo, president and chief executive officer at Aastrom Biosciences. 

If you liked this article you might like

Why Aastrom Biosciences (ASTM) Stock Is Soaring Today

Rev Shark: Market Chaos Theory

5 Stocks Under $10 Set to Soar

Biotech 2013 by the Numbers: A Blockbuster Year

Contrarian Ideas: Hedge Funds Are Selling These 10 Stocks Trading Below Target Price